Profile Of Viiv’s Unboosted Dolutegravir Emerges With First Phase III Results
This article was originally published in The Pink Sheet Daily
Executive Summary
Viiv Healthcare/Shionogi’s once-daily, unboosted integrase inhibitor dolutegravir is efficacious and well-tolerated in the first of four Phase III HIV trials to report, a study of treatment-naïve patients. Drug poses a competitive threat to Merck’s blockbuster Isentress and Gilead’s elvitegravir, part of the four-in-one “Quad” pill.
You may also be interested in...
Mutation Resistance Could Differentiate Shionogi/ViiV’s Dolutegravir
Full data from the Phase III SPRING-2 trial released at the International AIDS Conference revealed ViiV/Shionogi’s experimental integrase inhibitor dolutegravir had no resistance mutations compared to Merck’s Isentress.
Mutation Resistance Could Differentiate Shionogi/ViiV’s Dolutegravir
Full data from the Phase III SPRING-2 trial released at the International AIDS Conference revealed ViiV/Shionogi’s experimental integrase inhibitor dolutegravir had no resistance mutations compared to Merck’s Isentress.
Mutation Resistance Could Differentiate Shionogi/ViiV’s Dolutegravir
Full data from the Phase III SPRING-2 trial released at the International AIDs Conference revealed ViiV/Shionogi’s experimental integrase inhibitor dolutegravir had no resistance mutations compared to Merck’s Isentress.